Read more
Article
Daily News & Analysis
Sunday, July 13, 2008
Vadodara firm engineered Ranbaxy-Daiichi Sankyo deal
Local firm partnered with a US-based company to bring about the pact
Maulik Buch. Vadodara
The Ranbaxy-Daiichi Sankyo deal may have created a flutter in the pharmaceutical sector, but not many know that the pact was engineered by the Vadodara-based firm MP Advisors. The local firm, with support from the New York-based company Mehta Partners, brought together the Indian pharma giant, Ranbaxy and Japanese Daiichi-Sankyo to make the deal possible. Tarun Shah of MP Advisors said, "It all began with an idea. We started efforts in October 2007, and we were successful by June 2008. I and my partner flew down to Daiichi's Tokyo headquarters and made a simple proposition to the Japanese pharma giant. The rationale was that Daiichi was a successful Japanese company making patented, expensive innovator medicine with focus on top pharma markets of the US, Europe and Japan. On the other hand, Ranbaxy was a generic firm with a strong presence in key emerging markets, i.e. Romania, Africa, Ukraine, Brazil etc. and was trying hard to make an impact in the Japanese market.""The deal, however, debunked three myths. One, that innovators can never buy generics. Two, the Indian promoters will never sell their businesses and three, the Japanese are slow," he added. Since 1996, the Vadodara-based MP Advisors have come out with smart solutions for a number of pharma companies.
Daily News & Analysis
Sunday, July 13, 2008
Vadodara firm engineered Ranbaxy-Daiichi Sankyo deal
Local firm partnered with a US-based company to bring about the pact
Maulik Buch. Vadodara
The Ranbaxy-Daiichi Sankyo deal may have created a flutter in the pharmaceutical sector, but not many know that the pact was engineered by the Vadodara-based firm MP Advisors. The local firm, with support from the New York-based company Mehta Partners, brought together the Indian pharma giant, Ranbaxy and Japanese Daiichi-Sankyo to make the deal possible. Tarun Shah of MP Advisors said, "It all began with an idea. We started efforts in October 2007, and we were successful by June 2008. I and my partner flew down to Daiichi's Tokyo headquarters and made a simple proposition to the Japanese pharma giant. The rationale was that Daiichi was a successful Japanese company making patented, expensive innovator medicine with focus on top pharma markets of the US, Europe and Japan. On the other hand, Ranbaxy was a generic firm with a strong presence in key emerging markets, i.e. Romania, Africa, Ukraine, Brazil etc. and was trying hard to make an impact in the Japanese market.""The deal, however, debunked three myths. One, that innovators can never buy generics. Two, the Indian promoters will never sell their businesses and three, the Japanese are slow," he added. Since 1996, the Vadodara-based MP Advisors have come out with smart solutions for a number of pharma companies.
0 Reviews